After announcing that its phase 3 ATHOS-3 study would be published in a prestigious medical journal, clinical-stage biotech La Jolla Pharmaceutical (NASDAQ: LJPC) saw its shares ... David and Tom Gardner have a stock tip, it can …
Only 23% of the 158 placebo-treated patients had a blood pressure response compared to 70% of the 163 LJPC-501-treated patients. La Jolla Pharmaceutical gapped up sharply Monday and climbed during the first 45 minutes of trade. …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LJPC at https://www.zacks.com/ap/LJPC Keywords: La Jolla …
Yahoo!9mon
Based on fundamentals, market trends, company events and news, and other factors, equity analysts assign price targets and recommendations to buy or sell a stock. The following graph shows how a survey of multiple analysts recommend …
La Jolla Pharmaceutical Company announces U.S. Fda acceptance of new drug application for LJPC-501 * La Jolla Pharmaceutical Co- ‍user fee goal date under prescription drug user fee act is February 28, 2018 for LJPC-501 * La Jolla …
Since the March sell-off, LJPC's stock had mostly languished in spite of positive analysts' recommendations. However, by the end of 2014, the stock began a rally that has led to all-time highs in 2015. This article will provide the uninitiated …
For more information, get Portfolio Grader’s complete analysis of LEU stock. La Jolla Pharmaceutical Company. The company also gets F’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s …